PharmaEssentia Advocacy Group Partnership Recommendation
In July of 2020, I conducted thorough competitive and industry research to identify and analyze potential disease advocacy group partners for PharmaEssentia in advance of their March 2021 U.S. drug launch.
Over the course of my research, I identified 18 potential partners that aligned with PharmaEssentia’s business development needs and included information on key influencers, leadership, social followings, events, initiatives, and the current priorities.
I presented a strategic analysis and partnership recommendation to the CEO and GM of the Americas, along with other senior stakeholders at the rapidly growing publically-traded pharmaceutical firm. My recommendation included ways PharmaEssentia could capitalize on missed opportunities and accelerate user awareness among MPN patients and physicians.